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Association between duration of symptoms and severity of disease
at first presentation to paediatric rheumatology: results from the
Childhood Arthritis Prospective Study
N. Adib1,, K. Hyrich1,, J. Thornton1, M. Lunt1, J. Davidson2, J. Gardner-Medwin2, H. Foster3,
E. Baildam4, L. Wedderburn5 and W. Thomson1
Objectives. To study the association between disease severity at first presentation to paediatric rheumatology (PRh) and length of time since
symptom onset in children recruited to the Childhood Arthritis Prospective Study.
Methods. Children 16 yrs with inflammatory arthritis persisting 2 weeks were recruited from five UK hospitals. Data including
demographics, disease features, Childhood Health Assessment Questionnaire (CHAQ), physician and parent global assessment and blood
tests were collected at the first appointment with PRh (baseline). The association between symptom duration (defined as time from first
reported symptom onset to presentation at PRh) and baseline disease characteristics was evaluated using non-parametric descriptive
statistics and multivariable logistic regression analyses.
Results. Five hundred and seven children (65% female) were included: median age at onset was 6.8 yrs. Two hundred and thirty-three had
oligoarthritis, 68 had RF-negative polyarthritis, 27 had systemic onset arthritis and 29 had arthritis that was not JIA. The median symptom
duration was 4.6 months. Median symptom duration was shortest for children presenting with systemic arthritis (1.6 months) and longest for
those with PsA (8.6 months). Children with a longer duration of symptoms were older and had higher median active joint counts but lower
median ESR. Symptom duration did not correlate with CHAQ score at presentation.
Conclusions. Children who have systemic arthritis had the shortest delay to PRh presumably because they are profoundly unwell. Children
with joint pain/stiffness but normal ESR had longer delays suggesting that if blood tests do not indicate inflammation, the diagnosis of JIA may
be overlooked.
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Introduction
Each year 10/100 000 children develop inflammatory arthritis [1]
with many subsequently being diagnosed as juvenile idiopathic
arthritis (JIA). Many children continue to have some disability
and limitation of their activities of daily living and 50–70% are
estimated to have active disease into adulthood [2].
In adults with RA, guidelines from both ACR [3] and the
British Society for Rheumatology [4] emphasize the need for
early diagnosis and treatment to reduce subsequent functional
disability. Early disease-modifying drug intervention slows the
progression of structural joint damage and improves long-term
outcomes as well as overall quality of life [5]. The inherent
problem is the long lag time between onset of disease and referral
to rheumatologist for treatment with the length of time required to
make the diagnosis being the major contributor to this delay.
Arthritis in children is a different condition from adult inflam-
matory arthritis and one cannot directly extrapolate data from
adult disease to that of JIA. However, it is recognized that
arthritis in children should also be treated early and aggressively
to prevent significant structural damage and that clinicians should
not assume that JIA is a self-limiting condition that will remit as
the child grows [2].
Prompt diagnosis and referral to experienced care, ideally a
paediatric rheumatology (PRh) multidisciplinary team, are
essential and the UK Arthritis and Musculoskeletal Alliance
(ARMA) recommend in their ‘Standards of Care for People
with Inflammatory Arthritis’ (http://www.arma.uk.net/pdfs/ia.
pdf) that children with inflammatory arthritis should be assessed
by a specialist in rheumatology within 4 weeks of GP referral.
However, there remain few data on the factors associated with
delay to PRh care and the effects of this delay on both short- and
long-term outcomes. The aim of this initial study was to assess
whether there was an association between demographic and
disease characteristics at first presentation to a paediatric
rheumatologist and the length of time since first symptom onset.
Patients and methods
Patient selection
Children in this study were participants in the Childhood Arthritis
Prospective Study (CAPS), an ongoing prospective longitudinal
inception cohort study which aims to follow children presenting
with new onset inflammatory arthritis for a minimum of 5 yrs. The
overall aim of this study is to identify genetic and environmental
predictors of short- and long-term outcomes of inflammatory
arthritis (including response to treatment) in children and to
identify the relative contributions of socio-demographic, clinical,
psychological, laboratory and genetic factors and treatment in
explaining outcome. The study was launched in September 2001
and aims to recruit 1100 children from five tertiary referral centres
in England and Scotland: Royal Liverpool Children’s Hospital,
Liverpool; Booth Hall Children’s Hospital, Manchester; Royal
Victoria Infirmary, Newcastle; Royal Hospital for Sick Children,
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Glasgow; and Great Ormond Street Hospital, London. All
children aged 16 yrs either presenting to the PRh outpatient
clinic or admitted as inpatients, with newly diagnosed inflamma-
tory arthritis in one or more joints, which had persisted, accord-
ing to parent/child history for at least 2 weeks, are invited to
participate. Exclusion criteria are septic arthritis, haemarthrosis,
arthritis caused by malignancy or trauma, connective tissue
disorders such as SLE, MCTD or dermatomyositis. The initial
invitation was made by the paediatric rheumatologist and
followed-up by the research nurse after the parent had had time
to read the study information sheet.
CAPS was approved by the UK multicentre research ethics
committee. Written informed consent was obtained from the
parent(s)/guardian for all participant children according to the
Declaration of Helsinki [6], and children, if considered able, were
asked to provide assent.
Baseline data collection
Data for this study is collected from the PRh and the parent/child.
All children undergo a rheumatological exam at their first
appointment with the PRh (baseline). All children have an
active and limited joint count recorded as well as a physician
global assessment. At the first visit, the PRh is asked to assign
a ‘best guess’ ILAR classification, if the child is felt to have JIA
[7–9] or to indicate ‘Other inflammatory arthritis’ where appro-
priate. For this analysis, the ILAR classification is assigned at
baseline (and for many children within the first weeks of disease)
so can only be regarded as a predicted subtype. In addition, the
children’s clinical case notes are reviewed by a study research
nurse using standard data collection forms. Here, other disease
features relating to inclusion and exclusion criteria for ILAR
classification, as recorded in the clinical case notes, are collected
and include systemic rash, fever, lymphadenopathy, serositis,
psoriasis, nail pitting, dactylitis, enthesitis, sacroiliitis and uveitis.
Finally, the results from any laboratory investigations, if per-
formed, are recorded from the clinical case notes and include,
where undertaken, a full blood count, ESR and CRP, RF, ANA
and HLA-B27. The parent or, where appropriate, the child
completes a Childhood Health Assessment Questionnaire
(CHAQ) [10] including a parent general evaluation and pain
visual analogue scale (VAS).
Within 3 months of this PRh appointment, children and their
parents are interviewed by the specialist rheumatology research
nurse using a standard proforma and questionnaires either in the
clinic or at home. Data collected includes demographic details,
birth and health history as well as family history. The parent/child
is asked to recall the date of first symptom onset related to the
child’s arthritis. If an exact date is not known, the month and year
of symptom onset is recorded and the date set to the first of
the month.
Analysis
This preliminary cross-sectional analysis focuses on the disease
characteristics at presentation to PRh and their association with
time since first symptom onset. The total symptom duration was
calculated using the date of first reported onset of musculoskeletal
symptoms and the date of the first paediatric rheumatologist visit.
To further study the length of symptom duration in more detail,
the time was divided into two components: symptom onset up
to referral to PRh and the time between referral and PRh
appointment date. This was subsequently analysed according to
the source of the referral.
Presenting characteristics and median symptom duration are
given for the group as a whole and for each ILAR subtype, where
assigned. The total symptom duration was subsequently categor-
ized as a dichotomous variable (short and long symptom
duration) approximated to the cohort median and differences
between the two groups were compared using Wilcoxan rank sum
statistics for continuous variables and Pearson’s chi-squared test
for proportional variables. A multivariable logistic regression
model was developed to assess the independent association of
presenting characteristics with long symptom duration. The
resulting odds ratio (OR) is a measure of the probability of
having a symptom duration greater than the cohort median. All
analyses were undertaken using STATA version 9.2 (StataCorp,
4905 Lakeway Drive, College Station, TX 77845, USA).
Results
Characteristics at presentation to PRh
Up to 20 December 2006, a total of 507 children with inflammatory
arthritis were recruited to CAPS and included in this analysis. The
median age at symptom onset was 6.8 yrs and the median age at
first presentation was 7.8 yrs, 65% were female and 92% were
Caucasian (Table 1). At presentation, 427 (84%) were assigned a
JIA ILAR subtype: 233 (46%) children were classified as having
oligoarthritis (children were not yet assigned to either persistent or
extended oligoarthritis classifications), 68 (13%) had RF-negative
polyarthritis and 27 (5.3%) had systemic onset arthritis (Table 1).
Twenty-nine children (5.7%) were classified as having inflamma-
tory arthritis other than JIA, including 17 children with reactive
arthritis and 2 children with Down’s syndrome-associated arthritis.
In 51 children (10%), no specific diagnosis had been assigned and
further investigations were awaited.
For all children, the median number of joints with active
inflammation or limited range of movement were 1 [Interquartile
range (IQR) 1, 4] and 1 (IQR 0, 3), respectively (Table 2). The
median CHAQ score was 0.63 (IQR 0.13, 1.38). When the analysis
was limited to those children who had been assigned a JIA
subtype, CHAQ scores were higher in those with polyarthritis
(RF-positive and -negative) and systemic arthritis compared with
the other subtypes. Children presenting with systemic JIA had the
highest median ESR (93mm/h; IQR 60, 109) and CRP (98mg/l;
IQR 36, 246).
Symptom duration
The median symptom duration at the first presentation to PRh
was 4.6 months (IQR 2.3, 9.5) (Table 1). However, 108 (21%)
children had had symptoms longer than 1 yr. The shortest
symptom duration was seen in those children presenting with
systemic JIA (median 1.6 months; IQR 0.9, 5.6) and the longest in
those presenting with PsA (median 8.6 months; IQR 3.2, 29.3)
(Table 2).
The total symptom duration differed depending on the source
of the referral to PRh (Table 3), although the number of
physicians seen by the children prior to this referral was not
known. Most children (155; 37%), were referred from a general
paediatrician with a lesser proportion being referred via their
GP, orthopaedic, Accident and Emergency or another medical
specialist. The promptest referrals came via the Accident and
Emergency Department. The total symptom duration was longest
(median 7.8 months; IQR 4.6, 16.8) when children were referred
from other medical specialists, for example, plastic surgery,
neurology, ophthalmology, otolaryngology or adult rheumatolo-
gists. Once referred, 295 (62%) children were seen by a paediatric
rheumatologist within 4 weeks. For 17 children, the source
of the referral was missing. However, the median duration
of symptoms in this group (3.8 months; IQR 2.6, 7.5) was
similar to that seen among those children where the source
was known.
Total duration of symptoms and presenting disease
characteristics
As the median symptom duration was 4.6 months, the character-
istics associated with symptoms of 4 and >4 months were
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examined (Table 3). Additional analysis of those children with >6
and >12 months was also performed. For the cohort as a whole, a
total of 279 children (55%) had symptoms >4 months. Those with
longer symptoms had higher active and limited joint counts but
lower ESR and CRP compared with children with symptoms
4 months. Overall, 35% of the cohort had a normal ESR (defined
as 10mm/h) at first presentation to a paediatric rheumatologist.
However, only 22% of children with shorter symptom duration
(4 months) had a normal ESR at presentation compared with
46% of children with longer symptoms at first presentation
(P< 0.001). There was no difference in the predominance for either
upper limb or lower limb joint involvement between those with
shorter or longer total symptom duration (data not shown). There
was a trend towards those children with a longer symptom
TABLE 1. Demographics and disease characteristics of children with inflammatory arthritis at first appointment with paediatric rheumatologist
Whole cohort Systemic Oligoarthritis
Polyarthritis
RF negative
Polyarthritis
RF positive
Enthesits-
related arthritis PsA Undifferentiated
507 27 233 68 12 32 35 20
Demographics
Age at onset (yrs) 6.8 (3.0, 10.0) 6.4 (4.2, 9.8) 5.0 (2.4, 9.7) 6.7 (2.3, 9.6) 11.8 (9.4, 13.1) 11.6 (10.4, 13.3) 10.1 (6.3, 11.5) 6.4 (2.7, 11.9)
Female (%) 65 70 66 78 83 9 69 60
Caucasian (%) 92 96 92 97 84 97 100 89
Total symptom duration
(months)
4.6 (2.3, 9.5) 1.6 (0.9, 5.6) 4.4 (2.5, 8.6) 5.9 (2.6, 19.3) 6.2 (2.9, 33.2) 7.5 (3.6, 12.7) 8.6 (3.2, 29.3) 2.5 (1.2, 21.6)
Disease features
Number of joints with
active inflammation
1 (1, 4) 2 (0, 5) 1 (1, 2) 9 (5, 14) 9 (3, 25) 2 (1, 4) 3 (2, 10) 1 (1, 4)
Number of joints with
limited movement
1 (0, 3) 0 (0, 3) 1 (0, 2) 6 (1, 10) 7 (1, 16) 2 (1, 4) 2 (0, 6) 1 (1, 3)
CHAQ score (0–3) 0.63 (0.13, 1.38) 1 (0.25, 0.2) 0.63 (0.13, 1.25) 1.25 (0.38, 1.88) 1.0 (0.13, 1.75) 0.56 (0.13, 1.13) 0.56 (0.13, 1.38) 0.19 (0, 1.19)
Physician global
assessment (0–100)
35 (20, 60) 70 (57, 76) 26 (17, 47) 49 (30, 67) 50 (32, 81) 42 (29, 56) 30 (18, 57) 37 (21, 39)
Parent general evaluation
(0–100)
20 (5, 46) 32 (7, 48) 15 (3, 43) 32 (10, 53) 19 (15, 50) 30 (20, 53) 18 (4, 31) 21 (2, 48)
Pain (0–100) 34 (9, 60) 29 (9, 52) 30 (7, 50) 35 (13, 68) 55 (10, 68) 50 (38, 68) 28 (10, 64) 39 (2, 67)
ESR (n¼389) (mm/h) 21 (6, 46) 93 (60, 109) 17 (6, 35) 22 (5, 54) 15 (4, 30) 10 (5, 23) 26 (9, 47) 7 (2, 46)
ESR 10 mm/h, n(%) 137 (35) 0 66 (38) 22 (36) 4 (36) 10 (50) 9 (28) 8 (53)
CRP (n¼ 328) (mg/l) 9 (<5, 33) 98 (36, 246) 7 (<5, 16) 14 (4, 52) 12 (5, 33) 3 (<5, 21) 7 (<5, 15) 2 (<5, 59)
Acute uveitis, n(%) 7 (1.6) 0 4 (1.8) 1 (1.5%) 0 2 (6.3) 0 0
Chronic uveitis, n(%) 10 (2.0) 0 5 (2.2) 1 (1.5) 0 1 (3.1) 1 (2.7) 0
All results presented as median (interquartile range) unless otherwise specified.
TABLE 3. Association between baseline disease characteristicsa and symptom duration at first PRh assessment
Total cohort (n¼507)
Symptoms
4 months 228
Symptoms
>4 months 279 P-value
Symptoms
>6 months 215
P-value (compared
with 4 months)
Symptoms
>12 months 108
P-value compared
with 4 months
Age, (yrs) 6.5 (2.9, 10.8) 7.3 (3.2, 10.9) NS 7.4 (3.1, 11.2) NS 6.6 (2.9, 10.3) NS
Female, n (%) 141 (62) 186 (66) NS 140 (65) NS 68 (63) NS
Active joint count 1 (1, 3) 2 (1, 6) 0.005 2 (1, 6) 0.006 2 (1, 8) 0.001
Limited joint count 1 (0, 2) 1 (0, 4) 0.007 1 (1, 4) 0.005 2 (1, 4) 0.009
CHAQ (0–3) 0.75 (0.13, 1.38) 0.63 (0.13, 1.5) NS 0.63 (0.13, 1.50) NS 0.56 (0, 1.50) NS
Physician global assessment (0–100) 37 (20, 64) 33 (20, 56) NS 34 (20, 58) NS 35 (26, 57) NS
Parent global assessment (0–100) 18 (4, 47) 20 (5, 46) NS 20 (5, 45) NS 21 (5, 48) NS
Pain (0–100) 34 (6, 61) 34 (10, 60) NS 33 (10, 57) NS 33 (10, 60) NS
ESR (mm/h)b 32 (12, 57) 14 (5, 32) <0.001 11 (5, 30) <0.001 8 (4, 22) <0.001
ESR 10 mm/h, n (%) 39 (23) 98 (46) <0.001 79 (48) <0.001 45 (56) <0.001
CRP (mg/l) 12 (4,48) 7 (3, 20) 0.002 7 (0, 19) 0.0002 5 (0, 14) <0.001
Acute uveitis, n (%) 4 (1.8) 3 (1.3) NS 3 (1.4) NS 2 (1.9) NS
Chronic uveitis, n (%) 3 (1.4) 7 (2.6) NS 5 (2.4) NS 3 (2.9) NS
aResults are presented as median (Interquartile range) unless stated otherwise. bESR available in 389 children only (174 with oligoarthritis).
TABLE 2. Source of referral to first PRh appointment and total symptom duration in months prior to first assessment by PRh: median (IQR)
Source of referral n (% of whole cohort)a
Symptom duration between
symptom onset and referral
to rheumatology careb
Duration from date of
referral to PRh to first
PRh appointmentb Total symptom durationb
Totala 490 (97) 3.3 (1.5, 8.1) 0.8 (0.3, 1.7) 4.7 (2.2, 9.4)
Accident and emergency 44 (9) 1.1 (0.3, 3.2) 0.3 (0, 0.9) 1.7 (0.9, 4.3)
General practitioner 85 (17) 3.8 (1.6, 11.3) 1.3 (0.8, 2.3) 5.3 (3.2, 13.7)
Orthopaedic surgeon 147 (29) 3.3 (1.7, 7.8) 1.0 (0.5, 1.9) 5.1 (2.6, 9.7)
General paediatrician 185 (36) 3.3 (1.8, 8.3) 0.6 (0.2, 1.3) 4.6 (2.3, 9.0)
Otherc 29 (6) 5.4 (2.8, 13.3) 0.9 (0.3, 2.1) 7.5 (4.6, 14.3)
Not recorded 17 (3) – – 3.8 (2.6, 7.5)
aDate and source of referral only available for 490 children. bDifferences between referral sources statistically significant (Kruskal–Wallis equality-of-populations rank test, P< 0.001). cIncludes plastic
surgery, ophthalmology, otolaryngology, neurology, physiotherapy, adult rheumatology and direct parent referral.
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duration being older at symptom onset (7.3 vs 6.5 yrs) although this
did not reach statistical significance. There were no significant
differences in CHAQ, physician’s global assessment, parent’s
general evaluation and pain scores between the two groups. Very
few children had a diagnosis of uveitis at first presentation (7 with
acute uveitis and 10 with chronic uveitis), which did not differ
between those with longer and shorter symptom duration. It was
not known as to how many children had been referred to an
ophthalmologist prior to the first PRh consultation, but only three
children had been referred directly from an ophthalmologist
to PRh.
Using a multivariable logistic regression model, only ESR
remained an independent factor associated with total symptom
duration. In those children with a normal ESR at presentation, the
odds of a total symptom duration >4 months between symptom
onset and first appointment with PRh was 3.32 (95% CI
1.93, 5.69).
As some of these findings could be explained by the very short
symptom duration in those children presenting with systemic JIA,
a further analysis limited to those children assigned to the JIA
subtype oligoarthritis, the largest ILAR subtype, was undertaken
(Table 4). Again, longer total symptom duration was associated
with a lower ESR at presentation (10 vs 25mm/h; P< 0.001).
Those children with longer symptoms were also older at symptom
onset (6.1 vs 4.3 yrs; P¼ 0.03) but had a lower median CHAQ
score at presentation (0.50 vs 0.75; P¼ 0.04). There was also a
trend towards lower pain scores in patients with longer symptom
duration at first presentation, although this did not reach
statistical significance. Using a multivariable logistic regression
model, the strong association between a normal ESR and longer
symptom duration at presentation remained (OR 2.71; 95% CI
1.24, 5.92). In addition, the odds of longer symptom duration
increased by 9% for each increasing year of age at symptom onset
(OR 1.09; 95% CI 1.00, 1.19). CHAQ score was not independently
associated with a longer total symptom duration (OR 0.77; 95%
CI 0.45, 1.31).
Discussion
The results of this study demonstrate that many children have had
a long duration of symptoms prior to first assessment by
a paediatric rheumatologist, with a median total duration of
4.6 months. For >20% of children, this duration was >1 yr.
An interesting association between normal ESR at presentation
and longer duration of symptoms at first presentation might
suggest that a diagnosis of inflammatory arthritis may not be
considered in the setting of normal inflammatory markers, thus
delaying a referral to specialist PRh care. The symptom duration
was shortest in those presenting with systemic JIA, presumably
because these children are typically very unwell with high
inflammatory markers. The longest symptom duration was seen
among children with PsA. Although it is difficult to draw any firm
conclusions from this observation, the possibility exists that if
children are undergoing treatment for psoriasis, joint complaints
may be initially overlooked.
An audit of the delay in diagnosis of inflammatory arthritis in
42 children who presented over a 12-month period in Western
Australia found similar patterns to our study. The mean delay was
39.9 weeks (range 1–208 weeks) [11]. As in CAPS, Manners [11]
noted that the delay to diagnosis was significantly decreased if
ESR at presentation was high and the child had signs of active
inflammation. They found that the factors that did not affect
delay included subtype of inflammatory arthritis, the discipline of
referring practitioner, age at disease onset, presence of ANA,
HLA-B27, RF, visible swelling of joints, involvement of any
particular joint, number of joints and place of residence (rural
vs urban).
One limitation of this study was the accuracy with which the
date of symptom onset was recorded. It has been shown that the
ability of adults to recall the date of symptom onset becomes less
reliable with time since symptom onset [12], and therefore, is likely
to be most accurate for those with a very short duration. In
addition, for younger children, the date of symptom onset was
provided by the parent, who may have had difficulty in assigning
an accurate date. This may have affected our estimated median
symptom duration, although most likely this would have affected
the extremes of the estimates, for which the median would be least
affected. Our study is also limited by the lack of details regarding
the features present in the child when the disease first manifested,
and therefore, those presenting symptoms recorded in the CAPS
database may not necessarily be an accurate reflection of how ill
the child was in the early days/weeks of the disease. It is therefore
possible that certain characteristics, such as ESR, may have been
affected by interventions or therapies received before rheumatol-
ogy care, particularly if these children with a longer symptom
duration had received care by other medical specialists first.
However, this is unlikely to be the case for such a large proportion
of the cohort. For many of these children, they may have been
symptomatic for a significant length of time even before the parent
sought primary care. Delay in presenting to medical care after
onset of symptoms may arise because onset can be insidious and
signs and symptoms can be non-specific and parents may be
unaware of the severity of the problem. Other factors, such as
socio-economic status, may also influence this delay and could be
analysed in further studies.
TABLE 4. Association between baseline disease characteristicsa and symptoms duration at first PRh assessment (oligoarthritis only)
JIA: oligoarthritis only (n¼233)
Symptoms
4 months 107
Symptoms
>4 months 126 P-value
Symptoms
>6 months 92
P-value (compared with
4 months)
Symptoms
>12 months 46
P-value compared
with 4 months
Age, (yrs) 4.3 (2.4, 8.3) 6.1 (2.7, 10.2) 0.03 6.1 (2.5, 10.3) 0.05 6.1 (3.0, 10.2) NS
Female, n (%) 73 (68) 81 (64) NS 58 (63) NS 28 (61) NS
Active joint count 1 (1, 2) 1 (1, 2) NS 1 (1, 2) NS 1 (1, 2) NS
Limited joint count 1 (1, 1) 1 (0, 2) NS 1 (1, 2) NS 1 (1, 2) NS
CHAQ (0–3) 0.75 (0.13, 1.25) 0.5 (0, 1.13) 0.04 0.5 (0, 1.0) 0.02 0.25 (0, 0.75) 0.0046
Physician global assessment (0–100) 29 (19, 52) 27 (10, 43) NS 30 (10, 53) NS 33 (21, 62) NS
Parent global assessment (0–100) 12 (4, 43) 15 (4, 39) NS 15 (2, 40) NS 13 (2, 40) NS
Pain (0–100) 30 (5, 55) 26 (10, 50) NS 30 (10, 50) NS 30 (6, 48) NS
ESR (mm/h)b 25 (10, 42) 10 (5, 22) <0.001 10 (4, 26) 0.0003 7 (4, 22) <0.001
ESR 10 mm/h, n (%) 20 (26) 46 (48) 0.003 35 (52) 0.003 19 (56) 0.002
CRP (mg/l) 7 (1,16) 7 (0,16) NS 7 (0, 12) NS 7 (0, 10) NS
Acute uveitis, n (%) 3 (2.9) 1 (0.8) NS 1 (1.1) NS 1 (2.2) NS
Chronic uveitis, n (%) 2 (1.9) 3 (2.4) NS 2 (2.2) NS 1 (2.2) NS
aResults are presented as median (interquartile range) unless stated otherwise. bESR available in 389 children only (174 with oligoarthritis).
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Delays in referral to PRh may also occur after the child enters
medical care. Three published case reports describe children in
which diagnosis of inflammatory arthritis was delayed because of
non-recognition of early symptoms by parents and physicians [11].
UK trainees in paediatrics and primary care have reported low
self-confidence in their ability to assess a child’s musculoskeletal
system and poor documentation of musculoskeletal assessment
possibly as a result of inadequate training in rheumatology [13].
Based on the adult Gait, Arms, Legs, Spine screen, a musculo-
skeletal screening examination for children (pGALS) has now
been developed, which could be used to improve paediatric clinical
rheumatology skills [14]. Therefore, the delay will consist in both
the parent and child recognizing the illness, and subsequently, the
appropriate referral being made. A Brazilian study found that a
mean of 3.6 physicians (range 1–20) were consulted between onset
of symptoms and first consultation with paediatric rheumatolo-
gist, with a time interval ranging from a few days to 10 yrs
(mean 1.4) [15]. More recently, a UK study also found that
children with JIA had been referred to a median of 3 (0–5) medical
specialists prior to consultation with PRh. Despite this, most
children had untreated active disease at presentation and no child
had been referred for an ophthamological assessment [16]. In our
study, the longest delay occurred in those children who were
referred from routes other than general or musculoskeletal care.
Once referral was made, however, most children were seen within
4 weeks, according to ARMA standards.
Overall, we found that those children with the most severe
disease presented earlier and as a result, we could not demonstrate
a significant detrimental effect of prolonged symptom duration
prior to the first PRh visit. It is possible that those children
with the longest symptom duration had received at least some
appropriate treatment elsewhere. However, all children still
had some evidence of active disease at the time of this first
consultation, suggesting that any prior treatment had not been
definitive. What this study has not yet shown is whether or not
this ‘delay’ in reaching a paediatric rheumatologist will have long-
term detrimental effects. When 683 Italian children with JIA
were followed for 10 yrs, the probability of attaining remission
decreased in proportion to delay in entering tertiary care [17].
Children referred within 1 yr from disease onset had a statistically
significant higher remission rate than children referred 1–5 yrs or
>5 yrs of onset (35.7, 32.4, 22.8, respectively, P¼ 0.0124). Further
follow-up of our cohort will address this issue in the future.
In conclusion, this analysis has demonstrated that many
children subsequently diagnosed with inflammatory arthritis
have a significantly long period of symptoms prior to referral to
specialist care. Children with distinct signs and symptoms were
referred more quickly, particularly in the setting of raised
inflammatory markers. This is of concern as institution of
appropriate medical therapies and referral for ophthamological
assessment may therefore be delayed, possibly resulting in poorer
long-term outcomes such as irreversible joint deformity and
subsequent functional loss. Increased public awareness of this
condition as well as improvements to musculoskeletal training for
physicians may reduce the time taken to initial contact by patients
with the medical system as well as expedite appropriate referrals.
The strength of CAPS lies in its design. As a prospective inception
cohort of children presenting with inflammatory arthritis toPRh,
the influence of this ‘delay to presentation’ as well as other disease-
and treatment-related factors on outcome can be fully assessed.
Recruitment and follow-up of children to CAPS continues.
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Rheumatology key messages
 Many children with inflammatory arthritis have a significantly long
period of symptoms prior to referral to rheumatology.
 Normal blood tests, including ESR, do not preclude the diagnosis
of inflammatory arthritis.
JIA severity and symptom duration 995
